| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Qi, J. G. Lin, Y. L. Cao, J. Y. Wang, Q. C. Wu, G. Wang, Q. Liang, J. Zhao, Y. Yang, N. |
| Description |
Country affiliation: China Author Affiliation: Zhao Y ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Liang J ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Qi JG ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China 601127797@qq.com.); Yang N ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Wu G ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Lin YL ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Cao JY ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Wang Q ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.); Wang QC ( Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.) |
| Abstract |
Genome-wide studies have reported an association between the HNF1B rs4430796 (A>G) polymorphism and prostate cancer risk, but results have been inconsistent and recent meta-analyses have been inadequate. This study aimed to integrate previous results and explore the validity of this association. Electronic searches for all relevant publications through May 18, 2014, were conducted across several databases. Additional studies were identified manually, and only the most recent or complete were used in this meta-analysis. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Seven eligible case-control studies were identified, incorporating a total of 14,049 patients and 12,674 controls. Overall, we found that the rs4430796 (A>G) polymorphism had a decreased risk of prostate cancer (GG vs AA: OR = 0.661, 95%CI = 0.615-0.710, P = 0.304; AG vs AA: OR = 0.782, 95%CI = 0.739-0.828, P = 0.435; dominant model: OR = 0.743, 95%CI = 0.704-0.784, P = 0.912; recessive model: OR = 0.764, 95%CI = 0.718-0.813, P = 0.01). Furthermore, in the stratified analysis, there were significantly decreased risks among studies with population- and hospital-based controls. In the subgroup analysis by ethnicity, significantly decreased risks were also found among Caucasians, Americans, and Asians. Our results suggested that the HNF1B rs4430796 (A>G) polymorphism decreased the risk of prostate cancer. In the future, additional and larger studies on patients from across of the world might be required to validate our findings. |
| e-ISSN |
16765680 |
| Journal |
Genetics and Molecular Research |
| Issue Number |
3 |
| Volume Number |
14 |
| Language |
English |
| Publisher |
Fundação de Pesquisas Científicas de Ribeirão Preto |
| Publisher Date |
2015-07-03 |
| Publisher Place |
Brazil |
| Access Restriction |
Open |
| Subject Keyword |
Hepatocyte Nuclear Factor 1-beta Genetics Prostatic Neoplasms Case-control Studies Genetic Association Studies Genetic Predisposition To Disease Odds Ratio Polymorphism, Single Nucleotide Risk Factors Meta-analysis Discipline Genetics Discipline Molecular Biology Discipline Bioinformatics |
| Content Type |
Text |
| Resource Type |
Article |
